Cardiac surgery
The opioid-sparing result from breast surgery replicated in cardiac patients — a far higher-risk population.
TL;DR
Work from Baylor College of Medicine and the DeBakey VA examined tPEMF in coronary artery bypass (CABG) patients and found roughly a 70% reduction in morphine-equivalent dose. This is a much larger opioid-sparing signal than in the original soft-tissue trial, in a population where the stakes of opioid exposure are substantially higher.
Clinical work associated with Baylor College of Medicine and the Michael E. DeBakey VA Medical Center examined tPEMF in CABG patients and reported approximately a 70% reduction in morphine-equivalent dose versus the control group. This is a substantially larger opioid-sparing effect than the 2.2× (roughly 55%) reduction in the original breast-surgery trial.
Cardiac patients carry comorbidities that make opioids particularly risky: compromised respiratory reserve (can't tolerate respiratory depression), hemodynamic fragility (opioid-induced hypotension), impaired gut motility (ileus risk). Cutting morphine consumption by 70% in this population is not a comfort improvement — it is a complication-reduction intervention. This is also the population where length of stay is most expensive, which is why the hospital-stay finding that accompanied this result has direct economic implications.
CABG patients — a population with mean age in the 60s, high rates of diabetes, hypertension, and prior cardiac history — are among the most opioid-sensitive surgical patients because they have the most to lose from respiratory depression, hemodynamic instability, and impaired gut motility. The Baylor / DeBakey VA study measured total morphine-equivalent dose across the inpatient stay. The study setting — a high-volume academic cardiac surgery program — ensures the standard-of-care control is a meaningful benchmark rather than an under-treated comparison group.
Seventy percent less morphine after open-heart surgery means a patient who is more alert, breathing more effectively, and able to begin chest physical therapy and ambulation sooner. Each of those outcomes is a direct discharge determinant. The two-day shorter stay documented in the companion finding is the institutional expression of those individual clinical improvements. For the patient, it also means fewer opioid side effects — less constipation (ileus is a feared cardiac surgery complication), less delirium (a major driver of prolonged stays and long-term cognitive decline), and a lower dependence risk.
IV morphine PCA and scheduled IV opioids are the cornerstones of post-CABG pain management. Regional anesthetic techniques (thoracic epidural, paravertebral block) reduce but do not eliminate opioid use and carry their own procedural risks — coagulopathy concerns post-bypass make epidurals particularly complex. tPEMF contributes an additional opioid-reduction mechanism with no procedural risk, no drug-drug interactions, and no interaction with cardiac medications or anticoagulation. In a patient population where every additional pharmacologic intervention requires a careful risk-benefit analysis, a non-pharmacologic adjunct that produces a 70% reduction in opioid need is distinctively clean.
Sources & references
Related